TABLE 6.
Clinical outcomes at 1 year†.
| Intention-to-treat population |
As-treated set |
|||||||
| JBT group (N = 143) |
JWT group (N = 141) |
Difference (95% CI)* |
P-Value | JBT group (N = 140) |
JWT group (N = 138) |
Difference (95% CI)* |
P-value | |
| MACE | 8.4% (12) | 10.6% (15) | –2.3 (–9.1, 4.6) | 0.52 | 9.3% (13) | 10.1% (14) | –0.9 (–7.8, 6.1) | 0.81 |
| All-cause death | 0.7% (1) | 0.7% (1) | –0.01 (–1.96, 1.94) | 1.00 | 1.4% (2) | 0% (0) | 1.4 (–0.5, 3.4) | 0.50 |
| Cardiac death | 0.7% (1) | 0.7% (1) | –0.01 (–1.96, 1.94) | 1.00 | 1.4% (2) | 0% (0) | 1.4 (–0.5, 3.4) | 0.50 |
| Myocardial Infarction | 6.3% (9) | 7.1% (10) | –0.8 (–6.6, 5.0) | 0.80 | 6.4% (9) | 7.2% (10) | –0.8 (–6.8, 5.1) | 0.79 |
| Periprocedural MI | 5.6% (8) | 7.1% (10) | –1.5 (–7.2, 4.2) | 0.60 | 5.7% (8) | 7.2% (10) | –1.5 (–7.3, 4.3) | 0.60 |
| Any revascularization | 3.5% (5) | 5.0% (7) | –0.1.5 (–6.2, 3.2) | 0.54 | 3.6% (5) | 5.1% (7) | –1.5 (–6.3, 3.3) | 0.54 |
| TVR | 2.1% (3) | 2.8% (4) | –0.7 (–4.4, 2.9) | 0.72 | 2.1% (3) | 2.9% (4) | –0.8 (–4.4, 2.9) | 0.72 |
| TLR | 1.4% (2) | 2.1% (3) | –0.7 (–3.8, 2.3) | 0.68 | 1.4% (2) | 2.2% (3) | –0.8 (–3.9, 2.4) | 0.68 |
| Definite/probable stent thrombosis | 0.7% (1) | 1.4% (2) | –0.7 (–3.1, 1.7) | 0.62 | 0.7% (1) | 1.4% (2) | –0.7 (–3.2, 1.7) | 0.62 |
| Definite stent thrombosis | 0.7% (1) | 1.4% (2) | –0.7 (–3.1, 1.7) | 0.62 | 0.7% (1) | 1.4% (2) | –0.7 (–3.2, 1.7) | 0.62 |
Values are% (n). *The value is the difference between intentional strategy group and conventional strategy group.
†One year follow-up includes a window of ± 30 days. MACE was defined as a composite of all-cause death, MI (SCAI definition), or TVR. MACE, major adverse cardiac events; TVR, target vessel revascularization; TLR, target lesion revascularization; other abbreviations as in Table 1.